Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.
Type:
Grant
Filed:
April 22, 2005
Date of Patent:
December 11, 2007
Assignee:
ConjuChem Biotechnologies Inc.
Inventors:
Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique P. Bridon
Abstract: A fusion protein containing a polyhedrin of a virus and a foreign polypeptide sequence. Also disclosed are a recombinant occlusion body containing the fusion protein, an isolated nucleic acid containing a sequence encoding the fusion protein, and a recombinant virus containing the nucleic acid. Within the scope of this invention are related expression vectors, host cells, compositions, and preparation methods.
Abstract: A protein useful for clarifying the regulation mechanism of Ca2+-dependent exocytosis in particular, the activation and inactivation of Rab3A, and a method of screening for a material useful for regulating Ca2+-dependent exocytosis in particular, the activation and inactivation of Rab3A, using the above protein. By using the coimmunoprecipitation with an anti-Rab3A GEP antibody, a protein participated in the regulation of activation or inactivation of Rab3A is determined. As the protein binds to rabconnectin-3 and GDP/GTP exchange protein, it can be used for screening for a material that increases or decreases the binding.
Abstract: The invention relates to the genetic modification of plants, particularly to the expression of P-glycoprotein genes in transformed plants. Nucleotide sequences for the Br2 gene encoding a P-glycoprotein of maize and methods for their use are provided. The sequences find use in modifying the growth of plants.
Type:
Grant
Filed:
January 24, 2006
Date of Patent:
October 2, 2007
Inventors:
Gurmukh S. Johal, Dilbag S. Multani, Steven P. Briggs
Abstract: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.
Type:
Grant
Filed:
August 21, 2006
Date of Patent:
September 25, 2007
Assignee:
Bioprospecting NB Inc.
Inventors:
John M. Stewart, Bradley J. Steeves, Karl Vernes
Abstract: The invention relates to newly discovered marker polypeptides associated with endometriosis. Compositions, kits, and methods for detecting, characterizing, preventing, and treating endometriosis are provided.
Type:
Grant
Filed:
July 9, 2004
Date of Patent:
September 11, 2007
Assignee:
Praecis Pharmaceuticals Incorporated
Inventors:
Jeffrey Messer, Dennis Benjamin, James Vath, Eric Sigel
Abstract: Methods and compositions for producing secreted soluble receptors and biologically active polypeptides in trimeric forms are disclosed. The process involves fusing the DNA template encoding a soluble receptor with a ligand binding domain or biologically active polypeptide to a DNA sequence encoding a C-propeptide of collagen, which is capable of self-assembly into a covalently linked trimer. The resulting fusion proteins are secreted as trimeric soluble receptor analogs, which can be used for more efficient neutralization of the biological activities of their naturally occurring trimeric ligands.
Abstract: A felt for repairing soft tissue defects comprising a membranous collagen substrate and a bioresorbable fiber felted onto the collagen substrate. Methods of preparing a felt and methods of repairing soft tissue damage with a felt are also provided.
Abstract: A protein produced by gene recombinant technology, including at least one domain selected from domains I, II, and III of serum albumin but having a different structure from that of native albumin; and a method of producing the protein. The protein has an enhanced functional activity or activities selected from among various functional activities or serum albumin including antibacterial activity, antioxidative effect, inflammation inhibitory effect, in vivo substance transporting action, and enzymatic activity.
Type:
Grant
Filed:
January 28, 2005
Date of Patent:
August 7, 2007
Assignee:
Nipro Corporation
Inventors:
Masaki Otagiri, Yoshinori Kida, Naohisa Katayama, Toshiya Kai
Abstract: This invention describes the human gene homologue of the mouse gene previously identified. The human gene is located on the long arm of chromosome 17. The human gene, termed G1h, encodes for a protein, termed P1h, that substantially differs from the mouse protein. The human protein P1h can be used for immunosuppressive actions and clinical applications.
Type:
Grant
Filed:
October 22, 2004
Date of Patent:
August 7, 2007
Assignee:
The Research Foundation of State University of New York
Abstract: This invention relates to the use of amine, amino acid and amino acid ester mobile modifiers in normal phase chromatography to improve the resolution and or productivity of peptide and lipopeptide purification. This chromatographic method can be sued for either analytical or preparative scale purification.
Type:
Grant
Filed:
October 24, 2003
Date of Patent:
July 10, 2007
Assignee:
Merck & Co., Inc.
Inventors:
Kent E. Goklen, Joseph Nti-Gyabaah, Firoz D. Antia, Mary Ellen Dahlgren
Abstract: A mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) is useful for the inhibition of angiogenesis and/or tumor progression. Screening methods exist to identify compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.
Type:
Grant
Filed:
December 30, 2005
Date of Patent:
July 3, 2007
Assignee:
AngioGenetics Sweden AB
Inventors:
Anders Berkenstam, Göran Bertilsson, Lorenz Poellinger
Abstract: Synthetic versions of a full length and termini truncated humanized green fluorescent protein based on Ptilosarcus gurneyi are disclosed which have been modified to the favored or most favored codons for mammalian expression systems. The disclosed encoded protein has 239 amino acid residues compared with the wild type Ptilosarcus gurneyi which has 238 amino acids. In the present invention, a valine residue has been added at the second position from the amino terminus and codon preference bias has been changed in a majority of the wild type codons of Ptilosarcus gurneyi fluorescent protein. The humanized Ptilosarcus gurneyi green fluorescent protein is useful as a fluorescent tag for monitoring the activities of its fusion partners using imaging based approaches.
Abstract: This invention relates to plant defensin polypeptides, nucleic acids encoding them, and methods of use thereof. The invention also relates to a chimeric protein containing all or a portion of the plant defensin.
Type:
Grant
Filed:
September 30, 2004
Date of Patent:
July 3, 2007
Assignee:
E. I. DuPont de Nemours and Company
Inventors:
Omolayo O. Famodu, Rafael Herrmann, Albert L. Lu, Billy Fred McCutchen, Guo-Hua Miao, James K. Presnail, Zude Weng
Abstract: The present invention provides two novel E. coli synthetic promoters, Syn 1 and Syn 2. Syn 1 and Syn 2 are two tight regulated synthetic promoters that control uninduced, leaky expression of proteins that are toxic and interfere with production of recombinant protein from an E. coli expression system.
Abstract: It is intended to provide an anti-allergic agent, which efficaciously relieves symptoms accompanying an allergic disease without causing any serious side effect. This object is achieved by providing an anti-allergic agent which contains, as an effective ingredient, proteins collected from royal jelly or purified royal jelly, or royal jelly or purified royal jelly containing the proteins.
Abstract: The present invention provides a signal transducer specifically expressed in mouse mast cells that has the amino acid sequence of SEQ ID No. 2, a signal transducer specifically expressed in human mast cells that has the amino acid sequence of SEQ ID No. 4, polynucleotides encoding these proteins, an expression vector involving these polynucleotides, transformed cells induced by these expression vectors, and antibodies against the foregoing proteins. The signal transducer provided in the present invention is useful for screening of novel medicines against allergic diseases.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
June 5, 2007
Assignee:
Japan Science and Technology Corporation
Abstract: An object of the present invention is to provide a novel fluorescent protein derived from organisms other than Aequorea victoria. According to the present invention, there is provided a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 455 nm, and the fluorescence maximum wavelength is 488 nm; (2) the molar absorption coefficient at 455 nm is 38700 or 27700; (3) the quantum yield is 0.85 or 0.81; and (4) the pH sensitivity of the fluorescent property is stable at pH 5 to 9; and a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 548 nm, and the fluorescence maximum wavelength is 561 nm; (2) the molar absorption coefficient at 548 nm is 75900 or 51000; (3) the quantum yield is 0.44 or 0.50; and (4) the pH sensitivity of the fluorescent property is pKa<5.0.
Type:
Grant
Filed:
December 20, 2002
Date of Patent:
June 5, 2007
Assignees:
Riken, Medical & Biological Laboratories Co. Ltd.
Abstract: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.
Type:
Grant
Filed:
December 2, 2003
Date of Patent:
May 22, 2007
Inventors:
Thomas Nelson, Alessandro Quattrone, Daniel Alkon
Abstract: The invention relates to uses of GAG-peptide complexes and polypeptides obtained from connective tissue albeit indirectly which are substantially free of DNA for the treatment, protection and restoration of skin and connective tissues. The invention provides a topical composition comprising at least on GAG-peptide complex comprising two or three GAG-chains.
Type:
Grant
Filed:
May 16, 2005
Date of Patent:
May 1, 2007
Assignee:
Institute of Nutraceutical Research Pty. Ltd.